These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12595832)

  • 1. Beta-blockers and reverse remodeling: what are the implications?
    Francis GS; Tang WH
    Am Heart J; 2003 Feb; 145(2):200-2. PubMed ID: 12595832
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-blockers in asymptomatic dilated cardiomyopathy: to b-block or not to b-block?
    Filippatos G; Kremastinos DT
    Eur Heart J; 2007 May; 28(9):1170-1. PubMed ID: 17412729
    [No Abstract]   [Full Text] [Related]  

  • 3. Surrogate end points in heart failure trials.
    Gheorghiade M; Adams KF; Gattis WA; Teerlink JR; Orlandi C; O'Connor CM
    Am Heart J; 2003 Feb; 145(2 Suppl):S67-70. PubMed ID: 12594457
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment.
    Merlo M; Pyxaras SA; Pinamonti B; Barbati G; Di Lenarda A; Sinagra G
    J Am Coll Cardiol; 2011 Mar; 57(13):1468-76. PubMed ID: 21435516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction.
    Hamdani N; Paulus WJ; van Heerebeek L; Borbély A; Boontje NM; Zuidwijk MJ; Bronzwaer JG; Simonides WS; Niessen HW; Stienen GJ; van der Velden J
    Eur Heart J; 2009 Aug; 30(15):1863-72. PubMed ID: 19487234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta blockers in systolic heart failure: do physicians need more courage?
    Yilmaz MB; Refiker M
    Am Heart J; 2007 Nov; 154(5):e23; author reply e25. PubMed ID: 17967570
    [No Abstract]   [Full Text] [Related]  

  • 7. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversed reverse remodeling: can biomonitoring solve the clinical conundrum of the 3Rs?
    Januzzi JL; Hauptman PJ
    Circ Heart Fail; 2014 May; 7(3):388-90. PubMed ID: 24847126
    [No Abstract]   [Full Text] [Related]  

  • 9. Regression of normalized left ventricular systolic function after discontinuation of treatment in patients with dilated cardiomyopathy.
    Alahakoon PT; Binkley PF
    Congest Heart Fail; 2009; 15(5):245-6. PubMed ID: 19751427
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diastolic cardiac insufficiency].
    Spoto S; Palma Modoni A; De Galasso L
    Clin Ter; 2002; 153(5):355-7. PubMed ID: 12510423
    [No Abstract]   [Full Text] [Related]  

  • 11. Beta-Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy.
    Enzan N; Matsushima S; Ide T; Kaku H; Tohyama T; Funakoshi K; Higo T; Tsutsui H
    J Am Heart Assoc; 2021 Jun; 10(12):e019240. PubMed ID: 34053244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beta-blockers in cardiac insufficiency. Time to reconsider?].
    Follath F
    Schweiz Med Wochenschr; 1996 May; 126(18):747-9. PubMed ID: 8693298
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
    Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of beta-blockers in the pharmacologic treatment of congestive heart failure].
    Longo A
    Rev Port Cardiol; 1989; 8(7-8):563-8. PubMed ID: 2576636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NMR shows how beta blockers change the failing ventricle. Decreased size and better output performance].
    MMW Fortschr Med; 2003 Jun; 145(25):56. PubMed ID: 12891860
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neurohumoral systems escape control. Heart failure symptoms even once--long-term high risk prognosis].
    MMW Fortschr Med; 2005 Jul; 147(27-28):45. PubMed ID: 16041943
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
    Thornton PL; Ahmed A
    J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
    [No Abstract]   [Full Text] [Related]  

  • 18. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Blocker therapy in heart failure.
    Doughty RN
    Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.